ReviewJournal of biochemistry2026
The eIF5-mimic protein 5MP1: a regulator of translation stringency and a multifaceted oncogene.
Review in Journal of biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Accurate initiation of eukaryotic translation is essential for proteome integrity, yet the process is intrinsically challenged by the potential use of non-AUG start codons. The eIF5-mimic protein 5MP1 (also known as BZW2) has emerged as a pivotal regulator that enhances stringency in start codon selection by competing with eIF5 and eIF2B for binding to eIF2 and eIF3. This competition suppresses non-AUG and repeat-associated non-AUG (RAN) translation and remodels the dynamics of the scanning preinitiation complex. Beyond its biochemical role, accumulating evidence since the first report of BZW1/5MP2 as an oncogene in 2009 indicates that 5MP1/2 proteins promote proliferation, metastasis and poor prognosis across diverse cancer types. However, the downstream effectors and mechanistic pathways linking translation control to tumorigenesis remain incompletely defined. This review summarizes current biochemical understanding of 5MP1 in translation initiation and synthesizes evidence supporting its tumor-promoting activities, outlining key questions and future directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.